Pooled Analysis of Rivaroxaban therapy for acute venous thromboembolism in FIRST registry, SWIVTER and DRESDEN NOAC registry

BACKGROUND: The direct factor Xa inhibitor rivaroxaban is approved for the treatment of venous thromboembolism (VTE), based on the results of large phase III trials. OBJECTIVES: To confirm rivaroxaban's effectiveness and safety in routine clinical care of patients with VTE. METHODS: Data were o...

Descripción completa

Detalles Bibliográficos
Autores principales: Müller, Stephanie, Tittl, Luise, Speed, Victoria, Roberts, Lara, Patel, Jignesh, Patel, Raj, Arya, Roopen, Kucher, Nils, Spirk, David, Sahin, Kurtulus, Beyer‐Westendorf, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618466/
https://www.ncbi.nlm.nih.gov/pubmed/36324830
http://dx.doi.org/10.1002/rth2.12829

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618466/
https://www.ncbi.nlm.nih.gov/pubmed/36324830
http://dx.doi.org/10.1002/rth2.12829

Ejemplares similares